Zoetis (NYSE:ZTS) Hits New 52-Week Low – Here’s Why

Zoetis Inc. (NYSE:ZTS) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $71.00 and last traded at $72.1710, with a volume of 1329056 shares changing hands. The stock had previously closed at $73.79.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ZTS shares. Citigroup reduced their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. UBS Group cut their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Barclays decreased their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Finally, Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $109.62.

Zoetis Price Performance

The company has a market cap of $29.87 billion, a price-to-earnings ratio of 11.93, a price-to-earnings-growth ratio of 1.28 and a beta of 0.73. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a fifty day moving average price of $76.30 and a two-hundred day moving average price of $98.84.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s revenue was down .2% on a year-over-year basis. During the same period in the prior year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.19 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s dividend payout ratio is currently 34.93%.

Institutional Trading of Zoetis

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. University of Texas Texas AM Investment Management Co. acquired a new stake in Zoetis during the second quarter valued at approximately $25,000. Dunhill Financial LLC raised its holdings in shares of Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares in the last quarter. Prosperity Bancshares Inc bought a new position in shares of Zoetis during the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in Zoetis in the 1st quarter valued at $28,000. Finally, Root Financial Partners LLC boosted its stake in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.